eMedicine Specialties > Neurology > Pediatric Neurology

Chorea in Children

Author: William C Robertson Jr, MD, Professor, Departments of Neurology, Pediatrics, and Family Practice, Clinical Title Series, University of Kentucky
Coauthor(s): Ismail Mohamed, MD, Fellow, Department of Neurology, Children's Hospital of Michigan, Wayne State University; Bhagwan I Moorjani, MD, FAAP, FAAN, Consulting Staff, Department of Neuroscience, Director, Department of Neuroscience, Division of Evoked Response Laboratory, Children's National Medical Center
Contributor Information and Disclosures

Updated: Sep 23, 2008

Introduction

Choreiform movements are abrupt, irregular, and purposeless. They are quite brief, asymmetric, present at rest, and may persist during sleep.

The term chorea is derived from the Greek word for dancing and was applied initially to epidemics of dancing mania in the Middle Ages, in which large numbers of people danced together for days.

  • Many such dances were described, but the most renowned was chorea Sancti Viti (St. Vitus dance)
  • Sydenham used this term in his Schedula Monitoria to describe rheumatic chorea in 1686.1
  • Two hundred years later, Huntington described hereditary chorea and suggested that this movement disorder was similar to that described by Sydenham.2

Causes of Chorea

Inherited

  • Ataxia-telangiectasia
  • Benign hereditary chorea
  • Hallervorden-Spatz disease
  • Hereditary spinocerebellar ataxias
  • Huntington disease
  • Inborn errors of metabolism
    • Glutaric acidemia
    • Propionic acidemia
    • Homocystinuria
    • Phenylketonuria
    • Sulfite oxidase deficiency
  • Mitochondrial encephalomyopathies
  • Neuroacanthocytosis
  • Paroxysmal disorders
    • Paroxysmal kinesiogenic choreoathetosis
    • Paroxysmal nonkinesiogenic choreoathetosis
  • Pyruvate carboxylase deficiency
  • Wilson disease

Drugs

  • Anticholinergics
  • Anticonvulsants (eg, phenytoin, carbamazepine, phenobarbital)
  • Antidopaminergic agents (eg, phenothiazines, haloperidol, metoclopramide)
  • Antihistamines
  • CNS stimulants (eg, amphetamines, methylphenidate, pemoline)
  • Dopamine agonists (eg, levodopa)
  • Lithium
  • Oral contraceptives

Endocrine

Immune/infectious

Vascular

  • Arteriovenous malformation
  • Basal ganglia infarction or hemorrhage
  • Moyamoya

Metabolic

  • Hypocalcemia
  • Hypoglycemia and hyperglycemia
  • Hypomagnesemia
  • Hyponatremia, hypernatremia, and central pontine myelinolysis
  • Renal failure

Miscellaneous

  • Cerebral palsy
  • Head trauma
  • Bronchopulmonary dysplasia (infantile chorea)
  • Cardiopulmonary bypass - "Postpump chorea"

Neoplastic

  • Primary and metastatic brain tumors
  • Primary CNS lymphoma

Nutritional

Toxins

  • Carbon monoxide
  • Manganese
  • Organophosphate poisoning

Pathophysiology and General Principles in Treatment of Chorea

Movement disorders (particularly chorea, athetosis, and dystonia) are thought to result from basal ganglia pathology.

Connections of the basal ganglia can be categorized as follows:

  • Input from the cerebral cortex and the thalamus
  • Interconnections among the basal ganglia
  • Output from the basal ganglia to other nuclear masses

The main neurotransmitters associated with the basal ganglia include gamma aminobutyric acid (GABA), dopamine, acetylcholine, and glutamate. Other neurotransmitters include enkephalin, substance P, dynorphin, cholecystokinin, and somatostatin.

  • Dopamine is highly concentrated in the substantia nigra.
    • It is released in the postsynaptic area in the striatum from axons originating in the substantia nigra.
    • It is inactivated by reuptake in the presynaptic terminal and degraded by monoamine oxidase and catechol-O-methyltransferase.
  • GABA is concentrated mainly in the globus pallidus, the substantia nigra, and to a lesser extent in the caudate and the putamen.
    • It functions mainly in the interneurons of the striatum and the striatonigral pathways.
    • It is synthesized from glutamic acid by glutamic acid decarboxylase and is inactivated by GABA transaminase through the formation of a succinic semialdehyde.
  • Glutamic acid is an excitatory neurotransmitter that is involved primarily in the pathways leading from the cerebral cortex to the striatum.
  • Acetylcholine is active in both the central and peripheral nervous systems.
    • It exerts its greatest activity as a neurotransmitter in the striatum, hippocampus, and ascending reticular activating system.
    • It is synthesized from choline through choline acetyltransferase, which exerts its greatest activity in the caudate nucleus.
    • It is degraded by cholinesterase with the formation of choline, which may be used once again for synthesis by the presynaptic neuron.
  • Dopaminergic neurons within the substantia nigra project rostrally to the neostriatum (caudate and putamen).
    • The feedback loop from the neostriatum appears to be segregated into 2 parallel pathways.
      • The so-called indirect pathway consists of GABAergic/encephalinergic neurons that project to the external segment of the globus pallidus. Inhibitory neurons from the external globus pallidus synapse on neurons of the subthalamic nucleus, which then provide excitatory input (presumably glutamatergic) to the final output structures of the basal ganglia (the internal globus pallidus and the substantia nigra pars reticulata), which then inhibit the ventral thalamus.
      • The so-called direct pathway consists of GABAergic neurons that project directly to the internal globus pallidus and substantia nigra pars reticulata, inhibiting these nuclei.
    • The 2 output pathways are modulated differentially by dopamine. The GABA-containing neostriatal neurons that form the indirect pathway preferentially express dopamine type 2 receptors and are inhibited by dopamine, while the GABAergic neostriatal neurons that form the direct pathway tend to express dopamine type 1 receptors and are excited by dopamine.
    • Chorea may be viewed as resulting from increased dopaminergic activity in the projections from the substantia nigra to the striatum, resulting in decreased GABAergic projection from the striatum to the globus pallidus.
      • Most of the drugs used in symptomatic treatment of chorea act through attenuation of dopaminergic transmission or enhancement of GABA transmission.
      • Anticonvulsant drugs may suppress chorea but also may induce chorea, especially in patients with basal ganglia dysfunction.

Rheumatic (Sydenham) Chorea

Introduction

In 1684, Thomas Sydenham described the clinical syndrome that now bears his name. Originally termed St. Vitus' dance, it now is referred to as rheumatic chorea. Stoll first proposed a relationship between Sydenham chorea and rheumatic fever (RF) in 1780.

In 1889, Cheadle described the full rheumatic syndrome of carditis, polyarthritis, chorea, subcutaneous nodules, and erythema marginatum.3 Several decades later, epidemiologic and microbiologic studies confirmed the etiological role of streptococcal infection in RF.

More recently, Sydenham chorea (SC) has been linked to the obsessive-compulsive disorder (OCD) spectrum. Studies demonstrate a high prevalence of obsessive-compulsive symptoms as well as OCD in children with SC.

Epidemiology

Sydenham chorea is the most common cause of acquired chorea in the young. During the latter part of the twentieth century the number of reported cases of RF in the United States increased. This resurgence appears to be associated with strains of group A beta hemolytic streptococcal infection that are less likely to cause symptomatic pharyngitis.

  • In the United States, the incidence of RF is approximately 0.5-2 per 100,000 population per year.
  • The incidence of RF is clearly higher in developing countries, where the absence of consistent and early antibiotic treatment makes RF a more endemic problem.

Chorea is a major manifestation of acute RF and is the only evidence of RF in approximately 20% of cases. 

  • In some outbreaks, chorea has been present in more than 30% of patients with acute RF.
  • The female-to-male ratio is approximately 2:1, and most patients present between 5-15 years of age.

Family studies demonstrated a high frequency of a positive family history in patients with both SC and rheumatic fever. Aron et al found that 3.5% of parents and 2.1% of siblings of children with SC also were affected with SC.4

Clinical features and course

SC is a major manifestation of acute rheumatic fever.

  • According to the 1992 modification of the Jones criteria, chorea (or indolent carditis) alone is sufficient for diagnosis of RF, provided other causes have been excluded.5
  • SC typically presents with other manifestations of RF, but in 20% of cases chorea may be the presenting or sole manifestation of RF.

The main features of SC are involuntary movements, hypotonia, and mild muscular weakness. Chorea can be generalized or unilateral, predominantly involving the face, hands, and arms. Movements are present at rest and are aggravated by stress; the movements cease during sleep.

  • Children may attempt to hide the movements in quasi-purposeful actions (such as flinging hair back), or they may sit on their hands is an attempt to prevent these movements.
  • In about 20% of patients, one side of the body may be affected more severely than the other (hemichorea); however, careful examination usually reveals some  involvement of the opposite side.
  • The choreic movements interfere with volitional movements and result in a clumsy gait, dropping and spilling, and explosive bursts of dysarthric speech.
    • Muscular weakness leads to inability to sustain a contraction (milkmaid's grip).
    • The pronator sign consists of hyperpronation of the hands, causing the palms to face outward when the arms are held over the head. Another sign of weakness and hypotonia is the so-called choreic hand — with the arms extended, the wrist will flex and the metacarpophalangeal joints overextend.    
  • Some children may have such profound weakness that they appear paralyzed. Not uncommonly, children are restricted to bed or are unable to attend school for the duration of the illness. Fortunately, paralytic chorea is uncommon.

Patients with SC also present with a number of psychological and psychiatric manifestations such as depression, anxiety, personality changes, emotional lability, OCD, and attention deficit disorder (ADD).

  • Whether the psychological symptoms are secondary to the movement disorder or an integral part of the disease is not clear.
  • Occasionally, these symptoms precede the onset of the movement disturbance.

On average, the disease usually resolves spontaneously in 3-6 months and rarely lasts longer than 1 year.

  • Mild chorea without functional disability may be found in a small proportion of patients up to 10 years after the initial attack of SC.
  • About 20% of patients experience 2-10 recurrences, usually within 2 years after the initial attack.

Pathophysiology

Immunology: Evidence suggests that SC may result from the production of immunoglobin G antibodies that crossreact with antigens in the membrane of group A streptococci and  antigens in the neuronal cytoplasm of the caudate and subthalamic nuclei. Antineuronal antibodies have also been found in the cerebrospinal fluid (CSF) of patients with acute rheumatic chorea. Immunofluorescent staining has shown that sera from approximately half of the children with SC have antibodies that react with neuronal cytoplasmic antigens in the caudate and subthalamic nuclei. 

  • Serum antineuronal antibody titers have been found to decrease as the chorea improves.
  • In children who suffer a relapse, the increase in symptom severity correlates with a rise in these neuronal antibodies.

Neurochemistry: The main symptoms of SC are believed to arise from an imbalance among the dopaminergic system, intrastriatal cholinergic system, and inhibitory gamma-aminobutyric acid (GABA) system. Evidence of this imbalance has been suggested by the successful control of chorea by dopaminergic antagonists and valproic acid, a drug known to enhance GABA levels in the striatum and substantia nigra.

Neuroimaging                                                                                                                                         

MRI findings in SC are not consistent and may be normal. Published abnormalities include areas of increased signal intensity on T2-weighted images that usually involve the basal ganglia or cerebral white matter. One study reported an increase in basal ganglia volume consistent with localized swelling. Follow-up studies may show improvement but some residual abnormality is common.6

Functional neuroimaging using fluorodeoxyglucose (FDG) positron emission tomography (PET) has demonstrated reversible striatal hypermetaboli.

Diagnosis

Diagnosis of SC may be difficult, because no single, established diagnostic test is available.

  • SC usually develops in those aged 3-13 years and is believed to result from a preceding streptococcal infection. The patient may have no history of rheumatic fever, and a preceding streptococcal infection cannot always be documented. Infections can be subclinical and often precede the development of neurologic symptoms by age 1-6 months. At least 25% of patients with SC fail to have serologic evidence of prior infection.
  • Chorea may be the first and only manifestation of rheumatic fever. However, some patients may have subtle evidence of carditis by echocardiography despite a normal clinical examination and ECG. Chorea alone is sufficient for diagnosis providing other causes of the condition have been excluded.

Treatment

SC is usually self-limited, and treatment should be limited to patients with chorea severe enough to interfere with function.

  • Anticonvulsants (valproic acid and carbamazepine) have been shown to be effective in diminishing choreic movements at doses normally used for seizure control. 
  • Steroids have been used widely, but no controlled studies have been done to confirm steroid efficacy in chorea.
  • Dopaminergic blockers (pimozide and haloperidol) are effective and, when used in small doses, are usually well tolerated.

Parents and school officials should be informed that emotional lability is characteristic of this organic condition.

Immunologic treatment includes the following:

  • The presence of antineuronal antibodies suggests that intravenous immunoglobulin (IVIg) and plasma exchange may be effective.
  • Garvey and Swedo showed sustained improvement in 3 children treated with plasma exchange.7
  • Three other children treated with IVIG showed initial improvement but had recurrences after subsequent streptococcal infection.
Children with SC require prophylaxis against streptococcal infections until 18 years of age.

Juvenile Huntington Disease

Introduction

Huntington chorea is an autosomal-dominant, neurodegenerative disorder in which chorea is a primary clinical manifestation. Other prominent clinical features include progressive cognitive decline and an array of psychiatric disturbances.

The average age of onset is at 35-40 years; however, the disease has been reported in children as young as 4 years.

  • The age of onset varies among families, with some showing consistently older age of onset than others.
  • Age of onset among individuals of the same family also can vary widely; children of an affected father may have a younger age of onset than children of an affected mother.

The term juvenile Huntington disease designates patients whose clinical manifestations begin before the age of 20 years. This group also may be divided further into those with onset before the age of 10 years and those with onset in adolescence.

Genetics

Huntington disease (HD) is an autosomal-dominantly inherited disease with complete penetrance. The responsible gene, IT-15, is located on the p16.3 subband of chromosome 4. The genetic mutation is an unstable, expanded DNA trinucleotide (cytosine-adenosine-guanosine or CAG) repeat within the coding region for a 348-kD protein named huntingtin.

  • All individuals possess this repeat sequence; it is the number of triplet repeats that is significant. Patients with HD have 38 or more repeats. The earlier the age of onset, the greater the number of repeats for a given individual.
  • The correlation between repeat length and rate of disease progression is unclear. Approximately 10% of HD gene carriers develop signs of illness before age 20 years.
  • Between 70% and 80% of patients with childhood-onset HD have inherited the gene from an affected father.
  • Note that as many as 1% of individuals with HD may have a negative test result.

Clinical features

HD in the young presents differently than in adults. Initial stages in children include one or more of the following: mental deterioration or behavioral problems, rigidity with gait disturbance, cerebellar dysfunction, and occasionally seizures. Impaired ocular motility may also be an early sign of HD in the pediatric patient and resembles oculomotor apraxia.

  • The patient may appear to be primarily clumsy, rather than either rigid or choreiform.
  • Reflexes are usually brisk, and pyramidal signs with extensor plantar responses are common.
  • Seizures occur in about 30-50% of patients and are difficult to control.

Diagnosis

The availability of a DNA-based testing (to reliably identify the HD mutation) greatly facilitates diagnosis. The ability to determine the size of the trinucleotide repeat enables one to have accurate preclinical and prenatal diagnosis. Allele sizes of 40 or more CAG repeats are universally associated with the HD phenotype. 

Brain MRI and CT in juvenile HD may show caudate atrophy. MRI findings also include nonspecific increased T2 signal in the putamen. PET scanning in symptomatic patients using radiolabeled FDG uniformly shows a marked reduction in caudate glucose metabolism.

Presymptomatic testing should be executed only under rigid guidelines.

  • It should be performed only at the request of the patient.
  • Test results should be released only to the patient; if the result is to be released to another party, written consent is required from the patient.
  • Testing minors is considered inappropriate at this time, because results may have significant negative repercussions in raising the child.

Treatment

Presently, no specific therapy is available for HD. Management consists of symptomatic therapy and counseling.

  • Some patients benefit from antidepressants; carbamazepine may be useful for mood swings. Choline, reserpine, and dopamine antagonists may decrease choreiform movements.
  • Agents such as L-dopa or dopamine agonists can be helpful in the rigid form of the disease but may exacerbate chorea and provoke hallucinations and psychosis.

Experimental therapies (eg, agents that improve mitochondrial energy metabolism, agents that attenuate glutamate neurotransmission and free radical scavengers) have been ineffective.

Other Choreiform Disorders

Benign Hereditary Chorea

Introduction

Benign hereditary chorea (BHC) is a rare familial disorder with onset in early childhood. Transmission is autosomal dominant with the gene locus on chromosome 14q. However, rare cases of autosomal-recessive and X-linked inheritance have been reported.

The suggestion has been made that BHC could be allelic to HD. One family was reported to have expanded CAG repeats, suggesting that some families with the so-called benign chorea may in fact have a phenotypic variant of HD. More recently, de Vries demonstrated linkage between BHC and markers on chromosome arm 14q in a large Dutch family.

Clinical features

Chorea usually begins around the time the child is learning to walk but may occur throughout childhood. Most children only have chorea, which is nonprogressive and tends to diminish during adolescence. Associated features may include delayed motor development, dysarthria, intention tremor, athetosis, and hypotonia. Severity is highly variable but choreic movements are typically continuous and not episodic. Intellectual function is typically normal.

  • Intellectual impairment has been reported in one family in which affected individuals had intelligence quotient scores averaging 10 points lower than unaffected relatives.
  • Functional neuroimaging showed decreased striatal FDG metabolism in one study. Routine imaging and EEG results are normal.

Treatment

Various drugs have been used with mixed results. Commonly used drugs include anticonvulsants (phenytoin and carbamazepine), haloperidol, and prednisone. Dopamine antagonists appear to have the most benefit but should be reserved for significant cases as the chorea frequently does not require treatment.

Neuroacanthocytosis

Neuroacanthocytosis is a progressive multisystem disease with a wide range of symptoms. Characteristic features include acanthocytosis, normal beta-lipoprotein levels, and multiple movement disorders.

Genetics

Neuroacanthocytosis is most likely an autosomal-recessive disorder, although autosomal-dominant and X-linked inheritances have been proposed. In a recent genetic study, neuroacanthocytosis was linked to a 6-cM region of chromosome band 9q21.

Clinical features

Onset usually occurs in adults aged 20-40 years but may occur before age 10. In a large British survey of neuroacanthocytosis, the mean age for disease onset was 32 years. Death occurs approximately 10-20 years after onset.

Chorea is the most prominent finding, but dystonia, motor and vocal tics, and Parkinson features can also occur.

  • Oromandibular dystonia and orolingual dyskinesia commonly lead to dysarthria. Most patients have difficulty eating and swallowing early in the course of the disease. Lingual-labial dyskinesia may be so severe as to cause self-mutilation of the lips.
  • Axonal sensorimotor polyneuropathy with amyotrophy, elevated creatine phosphokinase (CK), and decreased or absent deep tendon reflexes also occurs.
  • Seizures occur in about one third of patients.
  • MRI may demonstrate atrophy of the caudate nucleus or T2-weighted hyperintensities in the striatum.

Diagnosis

Identify characteristic clinical features, a positive family history, the presence of acanthocytes on peripheral blood smear, and a normal plasma lipid profile.

Treatment

Treatment is symptomatic.

  • Antidopaminergic agents may suppress the chorea, but they may worsen concomitant parkinsonism.
  • Seizures should be treated with appropriate anticonvulsants.

Wilson Disease

Wilson disease is an inborn error of copper metabolism that may present with neurologic, hepatic, or psychiatric symptoms. It is inherited in an autosomal-recessive fashion.

In 1993, Bull et al suggested that Wilson disease is the result of a defect in the Wc1 gene (chromosome 13q14.3-q21.1) which encodes a copper transporting P-type adenosine triphosphatase that is expressed in the liver and kidney.8 Excess copper accumulates in the liver, brain, cornea, kidneys, and other tissues of untreated patients. Serum ceruloplasmin is low and excessive copper occurs in the plasma and urine.

Clinical features

Hepatic dysfunction is the initial feature in more than 50% of cases. Patients typically develop acute hepatitis that either resolves spontaneously or progresses to fulminant hepatic failure. Less common presentations are asymptomatic hepatomegaly, chronic active hepatitis, or cirrhosis.

  • Age at onset ranges from 3 to older than 50 years. Children younger than age 10 years usually present with hepatic failure unassociated with neurologic manifestations.
  • Untreated most individuals eventually develop neurologic dysfunction.
  • In 40% of individuals, neurologic symptoms are the presenting feature. These children typically present during the second decade of life.
  • Neurologic manifestations vary widely and may include chorea as well as dystonia, tremor, dysarthria, dysphagia, bradykinesia, and gait disorder. Most patients have gradual decline in school performance and intellectual abilities. Seizures are uncommon.
  • The average age of onset in those who present with neurologic symptoms is 18.9 years.

Almost all patients with neurologic involvement also have Kaiser-Fleischer rings, which result from deposition of copper in the Descemet membrane of the peripheral cornea.

Psychiatric manifestations include depression, personality changes, and emotional lability. Hemolytic anemia and renal tubular acidosis also may occur.

Diagnosis

Determining hepatic copper content via liver biopsy is the single most sensitive and accurate test for Wilson disease. Assay of serum ceruloplasmin is  simple and practical, but values are normal in 5-15% of affected patients. Other tests include the following:

  • Slit-lamp examination to check for the presence of corneal Kaiser-Fleischer rings is a vital part in the diagnostic evaluation.
  • Twenty-four-hour urinary copper excretion rises dramatically in symptomatic patients and is a useful test to monitor therapy.

Because of its protean manifestations, Wilson disease should be excluded in any patient who presents with unexplained neurological dysfunction, especially if the basal ganglia or cerebellum is involved.

Treatment

The 4 primary strategies for managing Wilson disease are as follows:

  • Limiting copper intake
  • Therapy to reduce copper absorption
  • Copper chelation therapy
  • Liver transplantation

Paroxysmal Choreas

Demirkiran and Jankovic divided paroxysmal dyskinesias into 4 groups according to the precipitating circumstances.9

  • Paroxysmal kinesiogenic dyskinesia
  • Paroxysmal nonkinesiogenic dyskinesia
  • Paroxysmal exertion-induced dyskinesia
  • Paroxysmal hypnogenic dyskinesia

Paroxysmal kinesiogenic dyskinesia

These choreas consist of any combination of these paroxysmal attacks: dystonia, chorea, athetosis, and ballismus. Goodenough et al noted choreoathetosis in 64% of patients.10 The age of onset ranges from 6-15 years. The attacks typically last less than 1 minute but occur frequently (more than 100 times per day).

  • The extremities are affected primarily, but facial, neck, and trunk muscles also can be affected.
  • The attacks may be disabling and interfere with walking, working, and daily activities.
  • Neurologic examination findings between the attacks are normal.

About half of the reported cases are familial, with both autosomal-dominant and -recessive patterns of inheritance. Multiple sclerosis, head trauma, thalamic infarcts, hypoparathyroidism, hypernatremia, and hyperglycemia represent common causes of secondary paroxysmal kinesiogenic dyskinesia.

The response to anticonvulsant medications is often striking.

  • Phenytoin has been considered the drug of choice and generally is used in dosages similar to those used in epilepsy; however, it also has been shown to be effective in smaller doses.
  • Satisfactory response has been obtained with other anticonvulsants, particularly carbamazepine; acetazolamide also may be used.
  • In one case, haloperidol worsened paroxysmal kinesiogenic dyskinesia.

Paroxysmal nonkinesiogenic dyskinesia

The attacks occur spontaneously without any specific precipitant. The duration ranges from 2-3 minutes to 4 hours, a major feature that differentiates it from paroxysmal kinesiogenic dyskinesia.

In one series, 81% of cases were familial. Multiple sclerosis is the leading cause of secondary paroxysmal nonkinesiogenic dyskinesia. Other causes include encephalitis, hypoparathyroidism, thyrotoxicosis, head injury, basal ganglia calcification, AIDS, and Leigh syndrome.

Attacks of paroxysmal nonkinesiogenic dyskinesia may diminish with age in frequency and severity.

It is more difficult to treat than paroxysmal kinesiogenic dyskinesia, since the nonkinesiogenic form does not respond to anticonvulsant drugs. Clonazepam (1-2 mg/d) appears to be the drug of choice; phenobarbital and valproic acid also may be effective.

Paroxysmal hypnogenic dyskinesia

This condition consists of brief, occasionally painful dystonic or choreoathetoid movements occurring during non–rapid eye movement sleep. In some cases, daytime kinesigenic or nonkinesiogenic attacks also have been described along with hypnogenic attacks. Short-lasting paroxysmal hypnogenic dyskinesia generally is regarded as a form of mesiofrontal epilepsy.

Paroxysmal exertion-induced dyskinesia

This disorder consists of attacks of dystonia, sometimes combined with chorea and athetosis, that are triggered by exertion such as walking or running. The attacks usually involve the lower limbs and are often bilateral. They may last from a few minutes to 30 minutes. Most of the described cases suggest an autosomal-dominant mode of inheritance. Treatment with anticonvulsants and levodopa has proven unsatisfactory.

Drug Treatment of Chorea

Dopaminergic blockers

  • Haloperidol
  • Pimozide

Dopaminergic depletors

  • Tetrabenazine
  • Reserpine

Benzodiazepines

  • Clonazepam
  • Diazepam

Anticonvulsants

  • Phenytoin
  • Carbamazepine
  • Valproic acid

Antidopaminergic agents

  • The hyperdopaminergic theory supports the use of dopamine antagonists.
    • In children, particularly those who will need treatment for long periods of time, neuroleptics present a potentially serious problem (ie, the risk of tardive dyskinesia).
    • Using neuroleptics only as a last resort is preferred.
  • The incidence of tardive dyskinesia in children is not known.
    • In a study of 41 children and adolescents who were treated with various neuroleptic medications, 3 patients had tardive dyskinesia.
    • Haloperidol should be started at a low dose (0.5-2 mg/d). Dose may be titrated gradually for a satisfactory response.
  • Aside from tardive dyskinesia, side effects include sedation, cognitive impairment, akathisia, acute dystonic reactions, and parkinsonism.
    • Pimozide (usually 0.2 mg/kg/d) may be associated with fewer side effects.
    • Baseline and follow-up ECGs are recommended to monitor for Q-T prolongation.
  • Tetrabenazine, a presynaptic dopamine depletor, also may be effective. It does not produce tardive dyskinesia, but side effects include depression, orthostatic hypotension, weight gain, and drowsiness.

Drugs acting through GABA

  • Benzodiazepines such as clonazepam and diazepam may be used to treat chorea, particularly in the early stages. Sedation is a major concern. They may be useful in the first few days until a satisfactory response to other drugs is achieved.
  • In one study, 15 children with SC were treated with sodium valproate (15-20 mg/kg/d) for a mean duration of 19.2 months. In 13 of the children, the choreiform movements disappeared within 1 week of beginning therapy.

Keywords

chorea, Sydenham's chorea, Sydenham chorea, juvenile Huntington's disease, juvenile Huntington disease, benign hereditary chorea, neuroacanthocytosis, Wilson's disease, Wilson disease, paroxysmal dyskinesias

 


More on Chorea in Children

References
[ CLOSE WINDOW ]

References

  1. Sydenham T. Schedula monitoria de novae febris ingressu. Londini, G. Kettilby. 1686.

  2. Huntington G. On Chorea. Med Surg Rep. 1872;26:317-321.

  3. Cheadle WB. Various manifestations of the rheumatic state as examined in childhood and early life. Lancet. 1889;1:821-827, 871-877.

  4. Aron AM, Freeman JM, Carter S. The Natural History of Sydenham'S Chorea. Review of the Literature and Long-term evaluation with Emphasis on Cardiac Sequelae. Am J Med. Jan 1965;38:83-95. [Medline].

  5. Special Writing Group of the AHA. Guidelines for the diagnosis of rheumatic fever. Jones Criteria, 1992 update. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. JAMA. Oct 21 1992;268(15):2069-73. [Medline].

  6. Giedd JN, Rapoport JL, Kruesi MJ, et al. Sydenham's chorea: magnetic resonance imaging of the basal ganglia. Neurology. Dec 1995;45(12):2199-202. [Medline].

  7. Garvey MA, Swedo SE. Sydenham's chorea. Clinical and therapeutic update. Adv Exp Med Biol. 1997;418:115-20. [Medline].

  8. Bull PC, Thomas GR, Rommens JM, et al. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet. Dec 1993;5(4):327-37. [Medline].

  9. Demirkiran M, Jankovic J. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol. Oct 1995;38(4):571-9. [Medline].

  10. Goodenough DJ, Fariello RG, Annis BL, et al. Familial and acquired paroxysmal dyskinesias. A proposed classification with delineation of clinical features. Arch Neurol. Dec 1978;35(12):827-31. [Medline].

  11. Aasly J, Skandsen T, Rø M. Neuroacanthocytosis--the variability of presenting symptoms in two siblings. Acta Neurol Scand. Nov 1999;100(5):322-5. [Medline].

  12. Abbas S, Khanna S, Taly AB. Obsessive-compulsive disorder and rheumatic chorea: is there a connection?. Psychopathology. 1996;29(3):193-7. [Medline].

  13. Beskind DL, Keim SM. Choreoathetotic movement disorder in a boy with Mycoplasma pneumoniae encephalitis. Ann Emerg Med. Jun 1994;23(6):1375-8. [Medline].

  14. Bird MT, Palkes H, Prensky AL. A follow-up study of Sydenham's chorea. Neurology. Jul 1976;26(7):601-6. [Medline].

  15. Bruyn GW, Myrianthopoulos NC. Chronic juvenile hereditary chorea. In: Vinken PH, Bruyn GW, Klawans HL, eds. Handbook of Clinical Neurology. Vol 49. Amsterdam: Elsevier Science Publishers; 1986:335-8.

  16. Campbell M, Grega DM, Green WH, et al. Neuroleptic-induced dyskinesias in children. Clin Neuropharmacol. 1983;6(3):207-22. [Medline].

  17. Cervera R, Asherson RA, Font J, et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore). May 1997;76(3):203-12. [Medline].

  18. Chadwick D, Reynolds EH, Marsden CD. Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. J Neurol Neurosurg Psychiatry. Dec 1976;39(12):1210-8. [Medline].

  19. Child Care Health Dev. Dyskinesias and associated psychiatric disorders following streptococcal infections. Child Care Health Dev. 2004 11;30(6):729.

  20. Comunale JP Jr, Heier LA, Chutorian AM. Juvenile form of Huntington's disease: MR imaging appearance. AJR Am J Roentgenol. Aug 1995;165(2):414-5. [Medline].

  21. Daoud AS, Zaki M, Shakir R, et al. Effectiveness of sodium valproate in the treatment of Sydenham's chorea. Neurology. Jul 1990;40(7):1140-1. [Medline].

  22. de Krom MC, Boreas AM, Hardy EL. [Manganese poisoning due to use of Chien Pu Wan tablets]. Ned Tijdschr Geneeskd. Oct 1 1994;138(40):2010-2. [Medline].

  23. Drake ME Jr, Jackson RD, Miller CA. Paroxysmal choreoathetosis after head injury. J Neurol Neurosurg Psychiatry. Jul 1986;49(7):837-8. [Medline].

  24. Fahn S. The paroxysmal dyskinesias. In: Marsden CD, Fahn S, eds. Movement Disorders 3. Oxford, England: Butterworth-Heinemann; 1994:75-6.

  25. Farrer LA, Conneally PM. A genetic model for age at onset in Huntington disease. Am J Hum Genet. Mar 1985;37(2):350-7. [Medline].

  26. Folstein SE, Chase GA, Wahl WE, et al. Huntington disease in Maryland: clinical aspects of racial variation. Am J Hum Genet. Aug 1987;41(2):168-79. [Medline].

  27. Gascon GG, al-Jarallah AA, Okamoto E, et al. Chorea as a presentation of herpes simplex encephalitis relapse. Brain Dev. May-Jun 1993;15(3):178-81. [Medline].

  28. Gordis L. The virtual disappearance of rheumatic fever in the United States: lessons in the rise and fall of disease. T. Duckett Jones memorial lecture. Circulation. Dec 1985;72(6):1155-62. [Medline].

  29. Gualtieri CT, Quade D, Hicks RE, et al. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Am J Psychiatry. Jan 1984;141(1):20-3. [Medline].

  30. Hadders-Algra M, Bos AF, Martijn A, et al. Infantile chorea in an infant with severe bronchopulmonary dysplasia: an EMG study. Dev Med Child Neurol. Feb 1994;36(2):177-82. [Medline].

  31. Hall JG, Te-Juatco L. Association between age of onset and parental inheritance in Huntington chorea. Am J Med Genet. Oct 1983;16(2):289-90. [Medline].

  32. Hardie RJ, Pullon HW, Harding AE, et al. Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain. Feb 1991;114 ( Pt 1A):13-49. [Medline].

  33. Hefter H, Mayer P, Benecke R. Persistent chorea after recurrent hypoglycemia. A case report. Eur Neurol. 1993;33(3):244-7. [Medline].

  34. Homan RW, Vasko MR, Blaw M. Phenytoin plasma concentrations in paroxysmal kinesigenic choreoathetosis. Neurology. Jun 1980;30(6):673-6. [Medline].

  35. Husby G, van de Rijn I, Zabriskie JB, et al. Antibodies reacting with cytoplasm of subthalamic and caudate nuclei neurons in chorea and acute rheumatic fever. J Exp Med. Oct 1 1976;144(4):1094-110. [Medline].

  36. IHA and WFN. Guidelines for the molecular genetics predictive test in Huntington's disease. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington's Chorea. Neurology. Aug 1994;44(8):1533-6. [Medline].

  37. Illarioshkin SN, Igarashi S, Onodera O, et al. Trinucleotide repeat length and rate of progression of Huntington's disease. Ann Neurol. Oct 1994;36(4):630-5. [Medline].

  38. Iqbal S, Sher MR, Good RA, et al. Diversity in presenting manifestations of systemic lupus erythematosus in children. J Pediatr. Oct 1999;135(4):500-5. [Medline].

  39. Joubert J, Joubert PH. Chorea and psychiatric changes in organophosphate poisoning. A report of 2 further cases. S Afr Med J. Jul 2 1988;74(1):32-4. [Medline].

  40. Kashihara K, Yabuki S. [Unilateral choreic movements in idiopathic hypoparathyroidism]. No To Shinkei. May 1992;44(5):477-80. [Medline].

  41. Kazis A, Kimiskidis V, Georgiadis G, Voloudaki E. Neuroacanthocytosis presenting with epilepsy. J Neurol. Jun 1995;242(6):415-7. [Medline].

  42. Kertesz A. Paroxysmal kinesigenic choreoathetosis. An entity within the paroxysmal choreoathetosis syndrome. Description of 10 cases, including 1 autopsied. Neurology. Jul 1967;17(7):680-90. [Medline].

  43. Kieburtz K, MacDonald M, Shih C, et al. Trinucleotide repeat length and progression of illness in Huntington's disease. J Med Genet. Nov 1994;31(11):872-4. [Medline].

  44. Konagaya M, Konagaya Y. MRI in hemiballism due to Sydenham's chorea. J Neurol Neurosurg Psychiatry. Mar 1992;55(3):238-9. [Medline].

  45. Korn-Lubetzki I, Brand A. Sydenham's chorea in Jerusalem: still present. Isr Med Assoc J. Aug 2004;6(8):460-2. [Medline].

  46. Korn-Lubetzki I, Brand A, Steiner I. Recurrence of Sydenham chorea: implications for pathogenesis. Arch Neurol. Aug 2004;61(8):1261-4. [Medline].

  47. Krauss JK, Mohadjer M, Nobbe F, et al. Bilateral ballismus in children. Childs Nerv Syst. Oct 1991;7(6):342-6. [Medline].

  48. Leli DA, Furlow TW Jr, Falgout JC. Benign familial chorea: an association with intellectual impairment. J Neurol Neurosurg Psychiatry. May 1984;47(5):471-4. [Medline].

  49. Lessof MN, Bywaters EGL. The duration of chorea. BMJ. 1959;30:1520-3.

  50. Lewis-Johnson J. Chorea: Its nomenclature, etiology and epidemiology in a clinical material from Malmhus county. Acta Pediatr. 1949;76:1910-1944.

  51. MacMillan JC, Morrison PJ, Nevin NC, et al. Identification of an expanded CAG repeat in the Huntington's disease gene (IT15) in a family reported to have benign hereditary chorea. J Med Genet. Dec 1993;30(12):1012-3. [Medline].

  52. MacMillan JC, Snell RG, Tyler A, et al. Molecular analysis and clinical correlations of the Huntington's disease mutation. Lancet. Oct 16 1993;342(8877):954-8. [Medline].

  53. Mark MH. Movement Disorders: Neurologicprinciples and practice. 38. McGraw-Hill; 1997:526-539.

  54. Marques-Dias MJ, Mercadante MT, Tucker D, et al. Sydenham's chorea. Psychiatr Clin North Am. Dec 1997;20(4):809-20. [Medline].

  55. Mayeux R, Fahn S. Paroxysmal dystonic choreoathetosis in a patient with familial ataxia. Neurology. Oct 1982;32(10):1184-6. [Medline].

  56. Mosquet B, Starace J, Madelaine S, et al. [Chorea-athetosis syndrome under the effect of carbamazepine and viloxazine. Consequence of drug interaction?]. Therapie. Nov-Dec 1994;49(6):513-4. [Medline].

  57. Myers RH, Goldman D, Bird ED, et al. Maternal transmission in Huntington's disease. Lancet. Jan 29 1983;1(8318):208-10. [Medline].

  58. Myers RH, Madden JJ, Teague JL, Falek A. Factors related to onset age of Huntington disease. Am J Hum Genet. May 1982;34(3):481-8. [Medline].

  59. Nausieda PA, Bieliauskas LA, Bacon LD, et al. Chronic dopaminergic sensitivity after Sydenham's chorea. Neurology. Jun 1983;33(6):750-4. [Medline].

  60. Nausieda PA, Grossman BJ, Koller WC, et al. Sydenham chorea: an update. Neurology. Mar 1980;30(3):331-4. [Medline].

  61. Nomoto M, Thompson PD, Sheehy MP, et al. Anticholinergic-induced chorea in the treatment of focal dystonia. Mov Disord. 1987;2(1):53-6. [Medline].

  62. Paulson GW, Reider CR. Movement disordersin children. In: Watts RL, Koller WC, eds. Movement Disorders: Neurologic Principles and Practice. Vol 49. McGraw-Hill;1997:61-672.

  63. Piccolo I, Causarano R, Sterzi R, et al. Chorea in patients with AIDS. Acta Neurol Scand. Nov 1999;100(5):332-6. [Medline].

  64. Pincus JH, Chutorian A. Familial benign chorea with intention tremor: a clinical entity. J Pediatr. May 1967;70(5):724-9. [Medline].

  65. Poewe WH, Kleedorfer B, Willeit J, Gerstenbrand F. Primary CNS lymphoma presenting as a choreic movement disorder followed by segmental dystonia. Mov Disord. 1988;3(4):320-5. [Medline].

  66. Pozzan GB, Battistella PA, Rigon F, et al. Hyperthyroid-induced chorea in an adolescent girl. Brain Dev. Mar 1992;14(2):126-7. [Medline].

  67. Profumo R, Toce S, Kotagal S. Neonatal choreoathetosis following prenatal exposure to oral contraceptives. Pediatrics. Oct 1990;86(4):648-9. [Medline].

  68. Rinne JO, Daniel SE, Scaravilli F, et al. The neuropathological features of neuroacanthocytosis. Mov Disord. May 1994;9(3):297-304. [Medline].

  69. Robertson WC Jr, Smith CD. Sydenham's chorea in the age of MRI: a case report and review. Pediatr Neurol. Jul 2002;27(1):65-7. [Medline].

  70. Rodopman-Arman A, Yazgan Y, Berkem M, et al. Are sensory phenomena present in Sydenham's Chorea? Evaluation of 13 cases. Neuropediatrics. Aug 2004;35(4):242-5. [Medline].

  71. Roos RA, Wintzen AR, Vielvoye G, et al. Paroxysmal kinesigenic choreoathetosis as presenting symptom of multiple sclerosis. J Neurol Neurosurg Psychiatry. Jul 1991;54(7):657-8. [Medline].

  72. Rubio JP, Danek A, Stone C, et al. Chorea-acanthocytosis: genetic linkage to chromosome 9q21. Am J Hum Genet. Oct 1997;61(4):899-908. [Medline].

  73. Scheinberg IH, Sternlieb I. Wilson's Disease. Philadelphia: WB Saunders; 1984.

  74. Shannon KM, Fenichel GM. Pimozide treatment of Sydenham's chorea. Neurology. Jan 1990;40(1):186. [Medline].

  75. Shulman LM, Singer C, Weiner WJ. Phenytoin-induced focal chorea. Mov Disord. Jan 1996;11(1):111-4. [Medline].

  76. Stone LA, Armstrong RM. An unusual presentation of diabetes: Hyperglycemia inducing hemiballismus(abstr). Ann Neurol. 1989;26:146.

  77. Suchowersky O, Hayden MR, Martin WR, et al. Cerebral metabolism of glucose in benign hereditary chorea. Mov Disord. 1986;1(1):33-44. [Medline].

  78. Swedo SE, Leonard HL, Schapiro MB, et al. Sydenham's chorea: physical and psychological symptoms of St Vitus dance. Pediatrics. Apr 1993;91(4):706-13. [Medline].

  79. Swedo SE, Rapoport JL, Cheslow DL, et al. High prevalence of obsessive-compulsive symptoms in patients with Sydenham's chorea. Am J Psychiatry. Feb 1989;146(2):246-9. [Medline].

  80. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. Mar 26 1993;72(6):971-83. [Medline].

  81. Thiebaut F. Sydenham's chorea. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology. Amsterdam: North Holland Publishing Co; 1968:409-434.

  82. Tison FX, Ferrer X, Julien J. Delayed onset movement disorders as a complication of central pontine myelinolysis. Mov Disord. 1991;6(2):171-3. [Medline].

  83. Truong DD, Harding AE, Scaravilli F, et al. Movement disorders in mitochondrial myopathies. A study of nine cases with two autopsy studies. Mov Disord. 1990;5(2):109-17. [Medline].

  84. Vance JM, Pericak-Vance MA, Bowman MH, et al. Chorea-acanthocytosis: a report of three new families and implications for genetic counselling. Am J Med Genet. Oct 1987;28(2):403-10. [Medline].

  85. Veasy LG, Wiedmeier SE, Orsmond GS, et al. Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med. Feb 19 1987;316(8):421-7. [Medline].

  86. Verheul GA, Tyssen CC. Multiple sclerosis occurring with paroxysmal unilateral dystonia. Mov Disord. 1990;5(4):352-3. [Medline].

  87. Walshe M. Wilson's disease (HLD). In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology. Vol 27. Amsterdam: North-Holland Publishing Co; 1976:379-414.

  88. Walshe M. Wilson's disease: The presenting symptoms. Arch Dis Child. 1962;37:253-6.

  89. Wang BJ, Chang YC. Therapeutic blood levels of phenytoin in treatment of paroxysmal choreoathetosis. Ther Drug Monit. 1985;7(1):81-2. [Medline].

  90. Weindl A, Kuwert T, Leenders KL, et al. Increased striatal glucose consumption in Sydenham's chorea. Mov Disord. Oct 1993;8(4):437-44. [Medline].

  91. Went L. Ethical issues policy statement on Huntington's disease molecular genetics predictive test. International Huntington Association. World Federation of Neurology. J Med Genet. Jan 1990;27(1):34-8. [Medline].

  92. Wheeler PG, Weaver DD, Dobyns WB. Benign hereditary chorea. Pediatr Neurol. Sep-Oct 1993;9(5):337-40. [Medline].

  93. Yimaz Y, Kocaman C, Ozdemir N. Carbamazepine in the Treatment of Chorea. Marmara Medical Journal. 2006;19(1):27-29.

  94. Zabriskie JB. Rheumatic fever: a model for the pathological consequences of microbial-host mimicry. Clin Exp Rheumatol. Jan-Mar 1986;4(1):65-73. [Medline].

  95. Zacchetti O, Sozzi G, Zampollo A. Paroxysmal kinesigenic choreoathetosis. Case report. Ital J Neurol Sci. Sep 1983;4(3):345-7. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

chorea, Sydenham's chorea, Sydenham chorea, juvenile Huntington's disease, juvenile Huntington disease, benign hereditary chorea, neuroacanthocytosis, Wilson's disease, Wilson disease, paroxysmal dyskinesias

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

William C Robertson Jr, MD, Professor, Departments of Neurology, Pediatrics, and Family Practice, Clinical Title Series, University of Kentucky
William C Robertson Jr, MD is a member of the following medical societies: American Academy of Neurology and Child Neurology Society
Disclosure: Nothing to disclose.

Coauthor(s)

Ismail Mohamed, MD, Fellow, Department of Neurology, Children's Hospital of Michigan, Wayne State University
Ismail Mohamed, MD is a member of the following medical societies: American Academy of Neurology and Child Neurology Society
Disclosure: Nothing to disclose.

Bhagwan I Moorjani, MD, FAAP, FAAN, Consulting Staff, Department of Neuroscience, Director, Department of Neuroscience, Division of Evoked Response Laboratory, Children's National Medical Center
Bhagwan I Moorjani, MD, FAAP, FAAN is a member of the following medical societies: American Academy of Neurology
Disclosure: Nothing to disclose.

Medical Editor

James J Riviello Jr, MD, George Peterkin Endowed Chair in Pediatrics, Professor of Pediatrics, Section of Neurology and Developmental Neuroscience, Professor of Neurology, Peter Kellaway Section of Neurophysiology, Baylor College of Medicine; Chief of Neurophysiology, Director of the Epilepsy and Neurophysiology Program, Texas Children's Hospital
James J Riviello Jr, MD is a member of the following medical societies: American Academy of Pediatrics
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Kenneth J Mack, MD, PhD, Senior Associate Consultant, Department of Child and Adolescent Neurology, Mayo Clinic
Kenneth J Mack, MD, PhD is a member of the following medical societies: American Academy of Neurology, Child Neurology Society, Phi Beta Kappa, and Society for Neuroscience
Disclosure: Nothing to disclose.

CME Editor

Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital
Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Amy Kao, MD, Assistant Professor, Department of Neurology, Department of Pediatrics, Division of Pediatrics, Oregon Health and Science University; Consulting Staff, Shriners Hospital
Amy Kao, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, American Epilepsy Society, and Child Neurology Society
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.